ArticleMolecular cell2018
The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 82 citations in OpenAlex.
- Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment.Nature genetics · 2026Article
- Insights from three decades of BRCA1/2 modeling in mice.Nature genetics · 2026Review
- Berry-derived gold nanoparticles induce integrated ROS-mediated apoptosis, immune modulation, and transcriptomic remodeling in 4T1 triple-negative cancer cells.Cell death discovery · 2026Article
- A novel dual histone mark reader ZCWPW2 regulates meiotic recombination through lactylation and transcriptional regulation in humans and mice.Nucleic acids research · 2026Article
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- Distinct mechanisms of recognition of phosphorylated RNAPII C-terminal domain by BRCT repeats of the BRCA1-BARD1 complex.The Journal of biological chemistry · 2026Article
- Saturation genome editing ofmedRxiv : the preprint server for health sciences · 2025Article
- Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer.Science advances · 2025Article
- Non canonical BRCA1 promotes cell survival via modulating PARP13-mediated SEC61G mRNA decay.Oncogenesis · 2025Article
- Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.Cancer discovery · 2025Review
- BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Genes & development · 2025Review
- Genome sequencing enhances the diagnostic yield and expands the genetic landscape of male breast cancer.Genetics in medicine open · 2025Article
- Integrating next-generation sequencing and artificial intelligence for the identification and validation of pathogenic variants in colorectal cancer.Frontiers in oncology · 2025Article
- BRCA1/BARD1 ubiquitinates PCNA in unperturbed conditions to promote continuous DNA synthesis.Nature communications · 2024Article
- BRCA1 and 53BP1 regulate reprogramming efficiency by mediating DNA repair pathway choice at replication-associated double-strand breaks.Cell reports · 2024Article
- Article
- BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair.Molecular cell · 2024Article
- Treatment of Sulfur Mustard Corneal Injury by Augmenting the DNA Damage Response (DDR): A Novel Approach.The Journal of pharmacology and experimental therapeutics · 2024Article
- Human HELQ regulates DNA end resection at DNA double-strand breaks and stalled replication forks.Nucleic acids research · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
David BillingInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Michiko HoriguchiInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Foon Wu-BaerInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Angelo TaglialatelaDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Giuseppe LeuzziDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Silvia Alvarez NanezDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Wenxia JiangInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Shan ZhaInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Matthias SzabolcsDepartment of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Chyuan-Sheng LinDepartment of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Alberto CicciaDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Richard BaerInstitute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: rb670@columbia.edu.
Columbia University Irving Medical Center · USCancer Genetics (United States) · USColumbia University · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1MThe Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYMINGTON, LORRAINE S · 2014 to 2024
$17.6MReplication fork remodeling and genomic stabilityR01CA197774 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alberto Ciccia · 2016 to 2026
$4.2MThe BARD1 tumor suppressor and breast cancerR01CA172272 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BAER, RICHARD J · 2013 to 2017
$1.7MThe role of the BARD1 BRCT domains in DNA repair and tumor suppressionF31CA200181 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BILLING, DAVID LEE · 2015 to 2016
$89kNCI NIH HHS F31 CA200181NCI NIH HHS P01 CA174653NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA172272NCI NIH HHS R01 CA197774NIGMS NIH HHS T32 GM007367
Abstract
The BRCA1 tumor suppressor preserves genome integrity through both homology-directed repair (HDR) and stalled fork protection (SFP). In vivo, BRCA1 exists as a heterodimer with the BARD1 tumor suppressor, and both proteins harbor a phosphate-binding BRCT domain. Here, we compare mice with mutations that ablate BRCT phospho-recognition by Bard1 (Bard1
Indexed as
AnimalsBRCA1 ProteinChromosomal InstabilityDNA Breaks, Double-StrandedDNA RepairFemaleHumansMiceMutationProtein DomainsRecombinational DNA RepairTumor Suppressor ProteinsUbiquitin-Protein LigasesBard1 protein, mouseBRCA1 ProteinBrca1 protein, mouseTumor Suppressor ProteinsUbiquitin-Protein LigasesBARD1BRCA1BRCT domainDNA break repairfamilial breast cancergenome instabilitypoly(ADP-ribose)stalled replication forkstumor suppression
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.